Becton Dickinson reports Q3 adjusted EPS $2.96, consensus $2.91

Reports Q3 revenue $4.88B, consensus $4.84B. “We continue to deliver strong results and this quarter is another reflection of our consistent execution against our BD 2025 goals.” said Tom Polen, chairman, CEO and president of BD. “Our teams are working unwaveringly to achieve key milestones that set us up for continued growth and consistent performance. We are very pleased to deliver our number one priority since launching BD 2025 – achieving 510(k) clearance for the updated BD Alaris(TM) Infusion System – allowing us to bring this updated system to our customers and their patients.”